Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
06 Dicembre 2023 - 10:05PM
Business Wire
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that
Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive
Officer, will present at the J.P. Morgan 2024 42nd Annual
Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT /
6:45 p.m. ET.
A live webcast of the presentation can be accessed under Events
& Presentations in the Investors section of the Vir website at
www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology
Vir Biotechnology, Inc. is an immunology company focused on
combining cutting-edge technologies to treat and prevent infectious
diseases and other serious conditions. Vir has assembled two
technology platforms that are designed to stimulate and enhance the
immune system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis delta and hepatitis B
viruses and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231206544466/en/
Media Carly Scaduto Senior Director, Media Relations
cscaduto@vir.bio +1 314-368-5189
Investors Sasha Damouni Ellis Executive Vice President,
Chief Corporate Affairs Officer sdamouni@vir.bio
Grafico Azioni Vir Biotechnology (NASDAQ:VIR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Vir Biotechnology (NASDAQ:VIR)
Storico
Da Giu 2023 a Giu 2024